Valuation: StemRIM

Market Cap 1.94TCr 12Cr 11Cr 9.68Cr 8.97Cr 17Cr 1.14TCr 17Cr 116.07Cr 45Cr 562.18Cr 45Cr 44Cr P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 1.24TCr 7.68Cr 6.72Cr 6.2Cr 5.74Cr 11Cr 729.1Cr 11Cr 74Cr 29Cr 359.83Cr 29Cr 28Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
47.55%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Director/Board Member 66 01/02/2007
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 12Cr
+4.07%+8.45%+25.67%-2.34% 6.88TCr
-0.24%-3.13%+49.38%+223.97% 5.52TCr
+1.21%+42.20%+42.20%+42.20% 4.35TCr
-0.04%+8.06%-50.00%-53.54% 4.12TCr
-2.48%+13.91%+166.79%-32.89% 3.17TCr
-1.32%-4.79%+58.07%-25.22% 3.04TCr
+2.10%+4.14%+75.49%+90.19% 2.36TCr
-0.57%+8.79%+4.91%+186.28% 1.93TCr
-0.04%+3.85%+67.76%+135.89% 1.72TCr
Average +0.26%+4.29%+48.92%+62.73% 3.67TCr
Weighted average by Cap. +0.72%+4.19%+43.38%+54.68%

Financials

2024 2025
Net sales - -
Net income -202.2Cr -1.25Cr -1.09Cr -1.01Cr -93.36L -1.77Cr -118.54Cr -1.8Cr -12Cr -4.7Cr -58Cr -4.69Cr -4.59Cr -192.9Cr -1.19Cr -1.04Cr -96.09L -89.07L -1.69Cr -113.08Cr -1.72Cr -12Cr -4.48Cr -56Cr -4.47Cr -4.38Cr
Net Debt -841Cr -5.19Cr -4.55Cr -4.19Cr -3.88Cr -7.37Cr -493.02Cr -7.49Cr -50Cr -20Cr -243.32Cr -20Cr -19Cr -699.4Cr -4.32Cr -3.78Cr -3.48Cr -3.23Cr -6.13Cr -410.01Cr -6.23Cr -42Cr -16Cr -202.35Cr -16Cr -16Cr
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
45
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B